Voyager Therapeutics, Inc. (VYGR) stock
VYGRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 9/3055% below fair value
$1.52−0.11 (-6.75%)
Close on Nov 17, 2026Market cap $93.66MP/E –Yield –
Voyager Therapeutics price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
Voyager Therapeutics's price to sales ratio was 3.1× on Nov 11, 2026, against 7.2× a year earlier. Over the last 5 years it ranged from 0.7× to 8.1×, with a median of 3.6×.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 3.1× | −3.8 |
| 2025 | Dec 31, 2025 | 7.0× | +5.1 |
| 2024 | Dec 31, 2024 | 1.9× | −3.3 |
| 2023 | Jan 31, 2023 | 5.2× | +1.8 |
| 2022 | Dec 30, 2022 | 3.3× | −3.1 |
| 2021 | Dec 31, 2021 | 6.4× | +5.1 |
| 2020 | Dec 31, 2020 | 1.4× | −5.6 |
| 2019 | Dec 31, 2019 | 7.0× | −18.4 |
| 2018 | Dec 31, 2018 | 25.4× | −45.4 |
| 2017 | Dec 29, 2017 | 70.8× | +51.6 |
| 2016 | Dec 30, 2016 | 19.3× | – |
See a number that looks wrong?